Cargando…

Plasma GDF15 levels associated with circulating immune cells predict the efficacy of PD-1/PD-L1 inhibitor treatment and prognosis in patients with advanced non-small cell lung cancer

PURPOSE: Although increased plasma growth differentiation factor-15 (GDF15) levels have been reported in patients with various cancers, the predictive role of PD-1/PD-L1 inhibitors in advanced cancers remains unknown. This study aimed to investigate GDF15 levels as a predictive marker in advanced no...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, Green, Sun, Pureum, Chung, Chaeuk, Park, Dongil, Lee, Song-I, Kim, Nayoung, Lee, Seong Eun, Lee, Jeong Eun, Kang, Yea Eun, Kang, Da Hyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889409/ https://www.ncbi.nlm.nih.gov/pubmed/36472770 http://dx.doi.org/10.1007/s00432-022-04500-5

Ejemplares similares

Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors
por: Kang, Da Hyun, et al.
Publicado: (2021)

Baseline Serum Interleukin-6 Levels Predict the Response of Patients with Advanced Non-small Cell Lung Cancer to PD-1/PD-L1 Inhibitors
por: Kang, Da Hyun, et al.
Publicado: (2020)

The rest period between chemotherapy and immunotherapy influences the efficacy of immune checkpoint inhibitors in lung cancer
por: Kang, Da Hyun, et al.
Publicado: (2022)

Pleural or pericardial metastasis: A significant factor affecting efficacy and adverse events in lung cancer patients treated with PD‐1/PD‐L1 inhibitors
por: Kang, Da Hyun, et al.
Publicado: (2018)

Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment
por: Haake, Markus, et al.
Publicado: (2023)

Changes in Oxygenation and Serological Markers in Acute Exacerbation of Interstitial Lung Disease Treated with Polymyxin B Hemoperfusion
por: Lee, Song-I, et al.
Publicado: (2022)

Programmed cell death ligand‐1 protein expression and CD274/PD‐L1 gene amplification in colorectal cancer: Implications for prognosis
por: Lee, Kyu Sang, et al.
Publicado: (2018)

The BTLA and PD‐1 signaling pathways independently regulate the proliferation and cytotoxicity of human peripheral blood γδ T cells
por: Hwang, Hyun J., et al.
Publicado: (2020)

Association between Growth Differentiation Factor 15 (GDF15) and Cardiovascular Risk in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
por: Shin, Min Young, et al.
Publicado: (2016)

PD-L1 Expression and Combined Status of PD-L1/PD-1–Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients
por: Han, Jiheun, et al.
Publicado: (2017)

Exercise increases circulating GDF15 in humans
por: Kleinert, Maximilian, et al.
Publicado: (2018)

GDF10 is related to obesity as an adipokine derived from subcutaneous adipose tissue
por: Song, Mi Kyung, et al.
Publicado: (2023)

Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines
por: Park, Ji-Eun, et al.
Publicado: (2020)

Transcriptional Regulation of GDF15 by EGR1 Promotes Head and Neck Cancer Progression through a Positive Feedback Loop
por: Jin, Yanli, et al.
Publicado: (2021)

Silibinin Regulates Tumor Progression and Tumorsphere Formation by Suppressing PD-L1 Expression in Non-Small Cell Lung Cancer (NSCLC) Cells
por: Rugamba, Alexis, et al.
Publicado: (2021)

The Influence of Sex on Characteristics and Outcomes of Coronavirus-19 Patients: A Retrospective Cohort Study
por: Lee, Song-I, et al.
Publicado: (2023)

Differential roles of GDF15 and FGF21 in systemic metabolic adaptation to the mitochondrial integrated stress response
por: Kang, Seul Gi, et al.
Publicado: (2021)

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
por: Janning, Melanie, et al.
Publicado: (2019)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
por: Lee, Hyun Tae, et al.
Publicado: (2017)

Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers
por: Kim, Jung Ho, et al.
Publicado: (2016)

Pivotal Role of Iron Homeostasis in the Induction of Mitochondrial Apoptosis by 6-Gingerol Through PTEN Regulated PD-L1 Expression in Embryonic Cancer Cells
por: Sp, Nipin, et al.
Publicado: (2021)

GDF15 Supports the Inflammatory Response of PdL Fibroblasts Stimulated by P. gingivalis LPS and Concurrent Compression
por: Stemmler, Albert, et al.
Publicado: (2021)

Antitumor Effect of Korean Red Ginseng through Blockade of PD-1/PD-L1 Interaction in a Humanized PD-L1 Knock-In MC38 Cancer Mouse Model
por: Lee, Eun-Ji, et al.
Publicado: (2023)

Prognostic implication of PD‐L1 polymorphisms in non‐small cell lung cancer treated with radiotherapy
por: Kang, Min Kyu, et al.
Publicado: (2021)

Tumor Infiltrating PD1-Positive Lymphocytes and the Expression of PD-L1 Predict Poor Prognosis of Soft Tissue Sarcomas
por: Kim, Jung Ryul, et al.
Publicado: (2013)

Sanguisorbae Radix Suppresses Colorectal Tumor Growth Through PD-1/PD-L1 Blockade and Synergistic Effect With Pembrolizumab in a Humanized PD-L1-Expressing Colorectal Cancer Mouse Model
por: Lee, Eun-Ji, et al.
Publicado: (2021)

PD-L1 and PD-1 expression correlate with prognosis in extrahepatic cholangiocarcinoma
por: Ma, Ke, et al.
Publicado: (2017)

Upregulation of Circulating PD-L1/PD-1 Is Associated with Poor Post-Cryoablation Prognosis in Patients with HBV-Related Hepatocellular Carcinoma
por: Zeng, Zhen, et al.
Publicado: (2011)

Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer
por: Kallergi, Galatea, et al.
Publicado: (2018)

Evaluation of circulating PD-1 and PD-L1 as diagnostic biomarkers in dogs with tumors
por: Song, Doo-Won, et al.
Publicado: (2021)

Kaempferol and Its Glycoside, Kaempferol 7-O-rhamnoside, Inhibit PD-1/PD-L1 Interaction In Vitro
por: Kim, Ji Hye, et al.
Publicado: (2020)

A preliminary study for the assessment of PD-L1 and PD-L2 on circulating tumor cells by microfluidic-based chipcytometry
por: Teo, Jinkai, et al.
Publicado: (2017)

Immune Deregulation in Sepsis and Septic Shock: Reversing Immune Paralysis by Targeting PD-1/PD-L1 Pathway
por: Nakamori, Yuki, et al.
Publicado: (2021)

The Inhibitory Mechanisms of Tumor PD-L1 Expression by Natural Bioactive Gallic Acid in Non-Small-Cell Lung Cancer (NSCLC) Cells
por: Kang, Dong Young, et al.
Publicado: (2020)

Preparation of Biphenyl-Conjugated Bromotyrosine for Inhibition of PD-1/PD-L1 Immune Checkpoint Interactions
por: Kim, Eun-Hye, et al.
Publicado: (2020)

Association between PD‐L1 expression and initial brain metastasis in patients with non‐small cell lung cancer and its clinical implications
por: Lee, Kyoungmin, et al.
Publicado: (2021)

Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab
por: Eun, Yeonghee, et al.
Publicado: (2019)

Effects of chlorinated Pd precursors and preparation methods on properties and activity of Pd/TiO(2) catalysts
por: Kim, Ye Eun, et al.
Publicado: (2020)

Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles
por: Orme, Jacob J, et al.
Publicado: (2020)

The Tri-iodothyronine (T3) Level Is a Prognostic Factor for Patients With Advanced NSCLC: Receiving Immune Checkpoint Inhibitors and Is Associated With Liver Metastasis
por: Kim, Yoonjoo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_atnvlce874iammder98vhpajeq